SFBC International Announces Upcoming Conference Call to Discuss Third Quarter 2005 Financial Results on October 27, 2005
Posted on: Wednesday, 12 October 2005, 09:01 CDT
SFBC International, Inc. (NASDAQ:SFCC), a provider of drug development services to branded pharmaceutical, biotechnology, generic drug and medical device companies, will release its financial results for the third quarter 2005 on Wednesday, October 26, 2005, after the market closes.
A live conference call and listen-only Webcast to discuss the results is scheduled for 10:00 a.m. Eastern Time on Thursday, October 27, 2005. To participate, please dial the following teleconference number (800) 275-3939 (Domestic) or (973) 409-9258 (International). A listen-only Webcast of the conference call will be available at http://www.sfbci.com.
For those unable to participate in the live conference, there will be an audio replay available from October 27, 2005 at approximately 12:30 p.m. Eastern Time through November 10, 2005 at 11:59 p.m. Eastern Time. To listen to the audio replay, please dial (877) 519-4471 (Domestic) or (973) 341-3080 (International) and use the following replay pin code: 6594264. A replay of the live Webcast will also be available at http://www.sfbci.com approximately two hours after the live call ends through November 26, 2005 at 11:59 p.m. Eastern Time.
About SFBC International, Inc.
SFBC International, Inc. provides early and late stage clinical drug development services to branded pharmaceutical, biotechnology, generic drug and medical device companies around the world. SFBC has more than 30 offices located in North America, Europe (including Central and Eastern Europe), South America, Asia, and Australia. In early clinical development services, SFBC specializes primarily in the areas of Phase I and early Phase II clinical trials and bioanalytical laboratory services, including early clinical pharmacology. SFBC also provides late stage clinical development services globally that focus on Phase II through IV clinical trials. SFBC also offers a range of complementary services, including data management and biostatistics, central laboratory services, medical and scientific affairs, regulatory affairs and submissions, and clinical IT solutions. Additional information is available on SFBC's website at http://www.sfbci.com.
Source: Business Wire
Related Articles
- Theratechnologies Presents Additional Results From Its Tesamorelin Phase 3 Studies at the 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
- SiDMAP Launches a Metabolomics Service for Early Detection of Drug-Induced Liver and Kidney Toxicity.
- A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
- Golden Eagle Signs Agreement for Consulting and Engineering Services With Washington Group International, Inc.
- Southwest Airlines Announces Intent to Resume Service to San Francisco International Airport
- KaloBios Commences Clinical Trial of Novel Antibody Rheumatoid Arthritis Drug Candidate
- MAXjet Airways Adds Aircraft to Fleet; All-Business Class Airline to Begin Service November 1, 2005
- China Is Seeing More and More Cases Of IT Outsourcing for Operations and Maintenance - Annual Analysis Report on Chinese IT Services Market (2005)
- Mergent's EventsData.Com North American Corporate Actions Service is Enhanced With International Data From London-Based EDI
- Air Charter to Provide Service From Baltimore/Washington International Airport to Ocean City
 |
 |
User Comments (0)
RSS Feeds